Article
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Jul 2020
Gris-Oliver Albert, Palafox Marta, Monserrat Laia, Brasó-Maristany Fara, Òdena Andreu, Sánchez-Guixé Mònica, Ibrahim Yasir H, Villacampa Guillermo, Grueso Judit, Parés Mireia, Guzmán Marta, Rodríguez Olga, Bruna Alejandra, Hirst Caroline S, Barnicle Alan, de Bruin Elza C, Reddy Avinash, Schiavon Gaia, Arribas Joaquín, Mills Gordon B, Caldas Carlos, Dienstmann Rodrigo, Prat Aleix, Nuciforo Paolo, Razavi Pedram, Scaltriti Maurizio, Turner Nicholas C, Saura Cristina, Davies Barry R, Oliveira Mafalda, Serra Violeta
Abstract excerpt
PURPOSE: AZD5363/capivasertib is a pan-AKT catalytic inhibitor with promising activity in combination with paclitaxel in triple-negative metastatic breast cancer harboring PI3K/AKT-pathway alterations and in estrogen receptor-positive breast cancer in combination with fulvestrant. Here, we aimed to identify response biomarkers and uncover mechanisms of resistance to AZD5363 and its combination with paclitaxel....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.